SEABOARD CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SEABOARD CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.81B | Feb 21, 2018 |
| FY2016 | Dec 31, 2016 | $5.38B | Feb 21, 2017 |
| FY2016 | Dec 31, 2015 | $5.59B | Feb 21, 2017 |
| FY2016 | Dec 31, 2014 | $6.47B | Feb 21, 2017 |
| FY2013 | Dec 31, 2013 | $6.67B | Feb 26, 2014 |
| FY2013 | Dec 31, 2012 | $6.19B | Feb 26, 2014 |
| FY2013 | Dec 31, 2011 | $5.75B | Feb 26, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.75B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $9.10B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $9.56B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $11.24B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $9.23B | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $7.13B | Feb 14, 2023 |
| FY2019 | Dec 31, 2019 | $1.81B | Feb 19, 2020 |
| FY2019 | Sep 28, 2019 | $1.66B | Feb 19, 2020 |
| FY2019 | Jun 29, 2019 | $1.82B | Feb 19, 2020 |
| FY2019 | Mar 30, 2019 | $1.54B | Feb 19, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.81B | Feb 21, 2018 |
| FY2016 | Dec 31, 2016 | $5.38B | Feb 21, 2017 |
| FY2016 | Dec 31, 2015 | $5.59B | Feb 21, 2017 |
| FY2016 | Dec 31, 2014 | $6.47B | Feb 21, 2017 |
| FY2013 | Dec 31, 2013 | $6.67B | Feb 26, 2014 |
| FY2012 | Dec 31, 2012 | $6.19B | Feb 27, 2013 |
| FY2011 | Dec 31, 2011 | $5.75B | Feb 28, 2012 |
| FY2011 | Dec 31, 2010 | $4.39B | Feb 28, 2012 |
| FY2011 | Dec 31, 2009 | $3.60B | Feb 28, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $693.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $576.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $316.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.03B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $818.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $574.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $446.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $550.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $549.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $497.00M | Feb 20, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $239.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $156.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($87.00M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $657.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $458.00M | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $134.00M | Feb 17, 2021 |
| FY2020 | Sep 26, 2020 | $39.00M | Feb 17, 2021 |
| FY2020 | Jun 27, 2020 | $9.00M | Feb 17, 2021 |
| FY2020 | Mar 28, 2020 | $63.00M | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | $89.00M | Feb 17, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $113.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $361.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $210.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $191.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $134.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $143.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $77.00M | Feb 17, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $454.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $420.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $403.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $373.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $360.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $329.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $336.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $314.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $309.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $267.00M | Feb 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $568.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $519.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $710.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $676.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $92.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $291.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $171.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $238.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $245.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $427.00M | Feb 20, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $562.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $511.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $506.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $474.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $460.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $259.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $349.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $162.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $173.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $158.00M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.25B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $7.67B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $7.57B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $7.90B | Feb 13, 2025 |
| FY2022 | Dec 31, 2021 | $7.50B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $6.40B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $6.35B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $5.31B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $5.16B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $4.76B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.01B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.92B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.93B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.89B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $3.07B | Feb 14, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.21B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.73B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.62B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $5.00B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $4.42B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.82B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $3.59B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $3.32B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $3.40B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.16B | Feb 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $164.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $160.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $154.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $163.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $167.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $164.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $167.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $22.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $19.00M | Feb 20, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.55B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.10B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $5.03B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $5.42B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $4.85B | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $4.29B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.03B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $3.73B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $3.75B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.47B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $178.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $98.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $56.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $199.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $75.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | $76.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $125.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $194.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $116.00M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $77.00M | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 514 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 90 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 202 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 499 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 490 | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | 222 | Feb 17, 2021 |
| FY2020 | Sep 26, 2020 | 132 | Feb 17, 2021 |
| FY2020 | Jun 27, 2020 | (23) | Feb 17, 2021 |
| FY2020 | Mar 28, 2020 | (88) | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | 148 | Feb 17, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 514 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 90 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 202 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 499 | Feb 13, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 957,794 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 971,055 | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 971,055 | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 1.16M | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | 1.16M | Feb 14, 2023 |
| FY2021 | Dec 31, 2020 | 1.16M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | 1.16M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | 1.17M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 1.17M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | 1.17M | Feb 21, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $9.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $10.00M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $10.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $10.00M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $10.00M | Feb 14, 2023 |
| FY2021 | Dec 31, 2019 | $10.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $7.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $7.00M | Feb 19, 2020 |
| FY2014 | Dec 31, 2012 | $14.38M | Feb 26, 2015 |